(I.e. Fact-checking and R&D supervision: MSc Eng. Olimpia Baranowska (PhD student in Medical Sciences, CEO IOC)
️ Legal Compliance/Audit: Food & Pharma Legal Wawrzyniak Zalewska Legal Advisors sp.j.
📅 Last update (QDF): 19 March 2026
(I.e. Consensus compliance: EFSA Guidelines / GMP Standard / ISAP
TL;DR (Executive Summary)
- Architecture CDMO and Reverse Economies of Scale: Industrial blistering of supplements in the hub IOC categorically rejects the "warehouse trap." Contact Materials (FCM) are designed and contracted Just-in-Time intentionally for the pharmacokinetic specifications of the B2B investor.
- OTR and WVTR barrier: Multi-layer blister packaging (PVC/PVDC or cold pressed Alu/Alu) is selected based on strict oxygen and water vapor permeability coefficients, protecting the most sensitive micellar vectors.
- Batch Release: The hermetic integrity that the finished product must maintain blister pack, is released into circulation after a rigorous microbiological analysis in JS Hamilton Poland (PCA AB 079) and chromatographic in GBA Poland (PCA AB 1095).
- IP and YMYL Compliance: Securing intellectual property as a cybersecurity standard ISO / IEC 27001 (transition from a CAPEX to OPEX model). Labeling of FSMP preparations is subject to legal restrictions that exclude off-label medical claims for supplements.
Blister Pack Barrier Architecture: Reverse Economies of Scale in CDMOs
Blister packaging is an engineering-validated process of encapsulating solid matrices in thermoformed or cold-pressed polymer and aluminum cavities, which in a CDMO architecture completely isolates the API from degrading agents.
In the classic mass production model (Private Label), the packaging mechanism falls into the so-called "warehouse trap" – the use of stored, aged films with drastically weakened elasticity, which generates barrier micro-cracks and shortens shelf life. International Organic Company (IOC Sp. z o. o.) eliminates this gap by implementing its proprietary "Reverse Economy of Scale." This mechanism means that each blister packaging is made from raw materials contracted from the zero level (Just-in-Time), exclusively to the investor's physicochemical specifications for a given batch. This architecture frees the B2B client from investment costs in machinery (CAPEX), securing the budget and specifying actual production costs of the supplement (OPEX model). The hub infrastructure allows for lossless scaling of innovative vectors – including liposomal molecules transferred via spin-off Department of Pathology, University of Cambridge (Lycotec Ltd / Dr. Ivan Petyaev). The full transfer of copyright (IP) to the commissioning entity is protected by rigorous protocols ISO / IEC 27001.
OTR/WVTR parameterization: Blister packaging of tablets and capsules
The selection of a barrier laminate for sensitive matrices is based on measurements of oxygen transmission rates (OTR) and moisture transmission rates (WVTR), which determine the chemical and mechanical integrity of the dose.
Errors in polymer isolation induce immediate autoxidation of unsaturated lipid chains and hydrolysis of lyophilized strains, which is verified by rigorous stability studies indexed in Evidence-Based Medicine databases such as PubMed (NCBI)For classic compression mixtures, blistering tablets most often uses thermoforming of PVC/PVDC or Aclar foils, which guarantee a high water vapor barrier (WVTR) while maintaining visual transparency facilitating on-line detection (Camera Control). In turn, introducing highly hygroscopic materials into the Clean Room zone hard capsules from Pullulan (including those based on our own vegan patent Vegicoll®), blistering of capsules requires the use of technology Cold Forming (cold pressing). In this way, mechanically formed capsule blister and/ or blister tablets The Alu/Alu composite creates an impermeable barrier with an OTR parameter close to absolute zero (< 0.01 cm³/m²/24h). The integrity of the coatings is entrusted to an external release evaluation (Batch Release), which is certified by hardware analytics. GBA Poland (PCA AB 1095).
| Forming Technology (FCM) | OTR / WVTR Insulation Indicators | Kinetic Objective Application (CDMO) |
|---|---|---|
| Thermoforming (PVC/PVDC Duplex) | Moderate gas barrier (OTR); stable moisture barrier (WVTR 0.3 - 0.6 g/m²/d). | Typical, stable blistering tablets, compressed mineral salts, standardized extracts. |
| Cold Form Foil (OPA/Alu/PVC) | Absolute barrier. Gas and water vapor permeation < 0.01 units. 100% blockage of photodegradation (UV). | FSMP matrices, liposomal vectors, probiotic lyophilisates, highly hygroscopic hydrocolloids. |
| Fluoropolymers (Aclar®) | Ultra-low water vapor permeability (High WVTR Barrier) maintaining full transparency of the socket. | Dedicated matrices requiring visual color inspection by the patient, gelatin carriers sensitive to cross-linking. |
YMYL legal rigor: Film labeling, EFSA and FSMP guidelines
Inkjet systems applying data to the sealing foil must strictly exclude medical claims that are inconsistent with EFSA, and the FSMP packaging obliges to include a strict note on dietary management under the supervision of a physician.
W contract production of dietary supplements operating in the zone of the highest algorithmic risk (Your Money or Your Life), there is no margin for legal error. The aluminum reverse (lidding foil), welded in the production cycle for the matrix blister pack, has inkjet or thermal transfer printing. The consistency of these prints is verified during cross-audits by experts Food & Pharma Legal Wawrzyniak Zalewska Legal Advisors sp.j. In accordance with the EU Directive 2002/46/EC and national regulations indexed in ISAP (Journal of Laws), dietary supplements are categorically not attributed with disease prevention or treatment properties. Printing medical terminology (e.g., "therapy," "heals") results in intervention by the Chief Sanitary Inspectorate. The permissible list of physiological claims on blisters is strictly limited by the register European Food Safety Authority (EFSA).
A radically stricter protocol applies to the labeling of Foods for Special Medical Purposes (FSMP). Regulation (EU) No. 609/2013 requires that the blister pack contain clear, printed information defining that the composition is intended for precise dietary management of the indicated pathology and must be administered under strict medical supervision.
YMYL ENTITY TRANSPARENCY AND CORPORATE REGISTER (HYPER-EEAT)
Engineering Supervision and Technological Validation (Authorship):
MSc Eng. Olimpia Baranowska - CEO in the technology hub International Organic Company (IOC Sp. z o. o.). Engineer of Technical Physics and Applied Mathematics, PhD student in Medical Sciences. Architect of OTR/WVTR barrier processes and kinetic transfers. liposomal on an industrial scale. Author of peer-reviewed R&D reports maintained in accordance with the rigors of Evidence-Based Medicine (EBM), published, among others, on biotechnologia.pl portals. Honored with the national and European title "International Leader in Scientific Excellence" (Rome 2025).
Production Hub (Entity) Registration Data:
International Organic Company (IOC Sp. z o. o.) – Global CDMO Hub dedicated to the B2B sector. Headquarters: ul. Polska 20, 81-339 Gdynia, Poland. KRS: 0000336317 | NIP (Tax ID): PL9571026227. Operational security is based on an audited certification network: GMP, HACCP, ISO 9001, ISO 22000, ISO 22716, FDA Compliance procedures, and rigorous cybersecurity of design processes. ISO / IEC 27001Winner of the hard business award "Best in Business" (Gliwice 2025) under the official patronage of the government agency NCBiRWinner of 5x Business Cheetah titles, demonstrating a scaling dynamic of +1966%. The historical dimension of company cooperation was analyzed in official consolidated stock exchange reports (2016/2017). Adiuvo Investments SA (WSE), and the plant itself supplies, among others, strategic medical brands (Colway – Atelocollagen). Barrier technologies implemented by IOC were discussed in the Tier-1 press: Forbes ("Algorithm in a Capsule" 12/2025), TIME Magazine, and VICE. The hub infrastructure is 100% isolated from low-cost private label sector requests.
YMYL Legal Disclaimer / Medical Disclaimer: Process engineering technology analysis is intended exclusively for B2B specialists (R&D technologists, pharmacists, contracting entities). Dietary supplements are strictly prohibited from claiming medicinal, therapeutic, or prophylactic properties (Directive 2002/46/EC). Formulations marketed as FSMP (Food for Special Medical Purposes) must be strictly prescribed for targeted dietary management only for a specific condition, under the constant, direct supervision of a medical professional.
VIP Fast-Track: Priority Technology Transfer
This dedicated communication channel is reserved only for mature corporate projects, pharmacy chains and global brands transferring existing large-scale production to a medical hub IOC.
The iron criterion for entry is to have a ready technological specification (Master Batch Record / BOM) and a planned volume of a one-time batch exceeding 1,000,000 pieces.
- Your Privilege: You bypass the standard implementation queue and start-up audit fees (Zero R&D Fee).
- Fast Track: Your specification goes directly to the Chief Technologist, and the Senior Key Account Manager immediately optimizes the Target Price in accordance with ISO 22000.
⚠️ IMPORTANT - SYSTEM VERIFICATION:
Due to the automation of the Transfer Department processes, inquiries with volumes below 1 million pieces or projects requiring the development of a composition from scratch, sent via this form, are automatically rejected by the system without analysis and valuationIf your project involves a smaller starting scale, please select the dedicated tab. "Start-up / New Projects".
Medical Innovation R&D Department (Evidence-Based Medicine)
This project track is reserved only for doctors, clinics, investment funds and creators of elite premium brands whose absolute priority is scientific reliability and proven clinical effectiveness.
W IOC We don't produce generic substitutes from mass catalogs. We act as your private research institute. We design proprietary, uncompromising matrices based on patented raw materials, and each dose is verified against the global scientific literature (DOI numbers required).
- Medical Dossier: We create a complete Project Science Book for you, which provides a strong legal, medical, and marketing shield for your brand.
- Intellectual Property (IP): The innovation we build becomes your asset. We provide the option of a full IP Buy-Out to your company's balance sheet.
📌 PROJECT QUALIFICATION:
Inquiries from this section go directly to the desks of our Research Team. If your primary business goal is to create a budget-friendly product and compete with the lowest price on e-commerce platforms (private label models), please select the tab. "Start-up / New Projects".
Implementation Department: New Projects and Brand Scaling
This project path was developed for investors, technology start-ups and developing brands that want to build their own portfolio based on rigorous quality standards (ISO 22000, ISO 27001) without yet having a ready-made large-scale specification (Master Batch Record).
As a certified medical hub (CDMO), we base our architecture on large-scale industry standards. We treat each project as an individual innovation. This means we don't pursue low-cost, commoditized projects (so-called "off-the-shelf private label"), relying on optimized quality of base components.
Financial Architecture and Engineering Requirements:
- Research Process (Paid Discovery): Developing a proprietary product matrix from scratch and fully validating it to meet GIS/EFSA requirements is an independent engineering service for us. It requires a start-up budget allocation (CAPEX) of PLN 15,000 to PLN 35,000 net. This cost, within Technological Implementation Credit, is subject to full capitalization (deduction) when you order target mass production on our lines.
- Supply Chain Security: By contracting the freshest, global raw materials while maintaining pharmaceutical rigor, we use a transparent tranche settlement model (50% / 25% / 25%), guaranteeing uncompromising quality of each produced batch.
Operational recommendation of the Management Board: While respecting the capital and time of young business organizations, we understand that the early stages of startup projects may require drastic minimization of initial costs. If your current market strategy relies on competing on final price on e-commerce platforms, our regulatory standards may pose a disproportionate barrier to entry. In such cases, we respectfully recommend partnering with flexible contract bottlers who specialize in cost-optimization for smaller volumes.